Introduction {#sec1}
============

Bladder cancer, as one of the most prevalent genitourinary malignancies, is characterized by its high recurrence and mortality rate \[[@cit0001]\]. Transitional cell carcinoma (TCC) represented 90% of all the bladder cancer cases diagnosed in the USA \[[@cit0002]\]. Although some achievements in chemotherapy regimens improved the therapies of bladder cancer, the 5-year survival rate of bladder transitional cell carcinoma (BTCC) patients still ranges from 48 to 66% \[[@cit0003]\]. Therefore, the development of new therapies is still desirable. Gemcitabine, a nucleoside antimetabolite that inhibits DNA synthesis, is one of the most often used anticancer drugs in the treatment of BTCC \[[@cit0004], [@cit0005]\]. However, the development of chemoresistance for gemcitabine has become one of the most important reasons for treatment failure and has resulted in relapse, metastasis or patient death \[[@cit0006]\]. In order to improve the therapeutic efficacy of BTCC, it is urgent to advance our understanding of mechanisms for gemcitabine-induced resistance and increase tumor cell sensitivity to gemcitabine \[[@cit0007]\].

The gene *DRAM2* (DNA-damage-regulated autophagy modulator protein 2), also known as *TMEM77* (transmembrane protein 77), encodes a 266-amino acid protein with six putative transmembrane domains \[[@cit0008]\]. Localized to lysosomal membranes, *DRAM2* plays a role in autophagy induction via promoting the conversion of endogenous LC3-I (microtubule-associated protein light chain 3) to the general autophagosome marker protein LC3-II (LC3-I/phosphatidylethanolamine conjugate) \[[@cit0009]\]. LC3 is required for the elongation of autophagosomes, which has two forms: LC3-I and LC3-II \[[@cit0010]\]. LC3-II, as the most reliable marker for quantification of cell autophagy, is up-regulated when LC3-I converts to LC3-II during autophagy \[[@cit0010]\].

Autophagy is a highly conserved process. The function of autophagy is to sequester parts of the cytoplasm, including damaged, superfluous organelles or long-lived proteins, into autophagosomes, which are double-membrane vesicles \[[@cit0007]\]. Autophagy serves an essential role in maintaining tissue homeostasis to support cell growth and survival \[[@cit0004]\], such as inflammatory bowel disease, neuronal degeneration, aging and cancer. On the other hand, many studies have reported that autophagy is a significant mechanism in chemoresistance, and inhibition of autophagy may enhance the sensitivity of cancer cells to chemotherapy \[[@cit0011]\], such as breast cancer, non-small cell lung cancer cells \[[@cit0012]\] and colorectal cancers \[[@cit0013]\].

Given these findings, we hypothesized that *DRAM2* mediates chemoresistance in bladder cancer cells. Therefore, we set out to test this hypothesis by investigating the relationship between *DRAM2* and autophagy in gemcitabine sensitive/resistance BTCC cells. The results determined the relationship between expression of *DRAM2* and autophagy, suggesting a promising new combination in the treatment of bladder transitional cell carcinoma.

Material and methods {#sec2}
====================

Integrated analysis of microarray datasets {#sec2.1}
------------------------------------------

The microarray data in the GEO database (accession number GSE77883) at the National Center for Biotechnology Information Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>) under GPL19117 were used to analyze the six samples (three T24 cells and three T24-GEM cells). Differentially expressed mRNAs related to autophagy were identified based on the criteria of over 2-fold expression change within different groups and a *p*-value less than 0.05.

Cell culture {#sec2.2}
------------

Bladder transitional cell carcinoma cell lines T24 (TCHu 55) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI 1640 (Roswell Park Memorial Institute, Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 ug/ml streptomycin. Gemcitabine-resistant BTCC cells (T24-GEM) were derived by treating T24 cells with 5 µg/ml gemcitabine and maintained in the same condition for more than 6 months. The T24-GEM cells were cultured in complete medium supplemented with 12% FBS, 5 µg/ml gemcitabine, 100 U/ml streptomycin and 100 U/ml penicillin. Cells were incubated at 37°C with 5% CO~2~ in an incubator.

Real-time PCR analysis {#sec2.3}
----------------------

Total RNA was prepared from T24/T24-GEM cells transfected with DRAM2/si-DRAM2 according to the manufacturer's instructions and the concentration of total RNA was determined. The RNA was then reverse transcribed in a 20 µl reaction mixture according to the instructions of the RevertAid First strand cDNA syntherio Kit (Fermentas, China). The PCR program for DRAM2 and GAPDH (Santa Cruz Biotechnology, CA, USA) included one cycle at 95°C for 2 min, 39 cycles at 95°C for 20 s, 65°C for 20 s, 72°C for 30 s, and finally extension at 72°C for 10 min. The PCR products of the DRAM2 gene and internal controls were detected by electrophoresis in agarose gel. All DNA fragments and resulting clones were verified by sequencing.

Western blot {#sec2.4}
------------

Cells and tissues were lysed with ice-cold RIPA buffer (Beyotime, Shanghai, China) supplemented with phenylmethanesulfonyl fluoride (PMSF) and protease inhibitor cocktail (Roche). Cell protein lysates were subjected in 10% sodium dodecyl sulfate-polyacrylamide gels, electrophoretically transferred to polyvinylidene difluoride membranes (Roche). Total protein concentration was measured using a BCA protein assay kit before loading for SDS-PAGE. The membranes were incubated with 5% skim milk, washed and then incubated with the rabbit anti-human DRAM2 (1 : 500 dilution) or GAPDH (1 : 1000 dilution) overnight at 4°C, followed by incubated with goat anti-human horseradish peroxidase antibody for 1 h at 37°C. All antibodies were purchased from Abcam (Abcam, USA). The proteins were perceived by the enhanced chemiluminescence kit (Invitrogen) and exposed to X-ray film. Protein expression levels were normalized to GAPDH.

Cell transfection {#sec2.5}
-----------------

Human DRAM2 cDNA and si-DRAM2 were chemically synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). The oligonucleotides were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. Cells were subcultured 1 day before the transfection and were inoculated into 6-well plates. After cell confluence reached 90--95%, 50 µl of serum-free medium was used to dilute 1.0 µg of DNA, and then another 50 µl of serum- free medium was used to dilute 1 µl of Lipofectamine 3000 transfection reagent. Subsequently, the solution was mixed with the diluted DNA at room temperature for 20 min and added to each well. Cells were generally assigned to different groups as follows: (1) NC group (transfected with Lipofectamine 2000), siRNA control group and si-*DRAM2* group (T24-GEM cells); (2) NC group (transfected with Lipofectamine 2000), pcDNA3.1 control group, pcDNA3.1-*DRAM2* group (T24 cells). The transfection efficiency was observed under qRT-PCR and western blot, and siRNA sequences are listed in [Table I](#t0001){ref-type="table"}.

###### 

Primers used in the study

  Gene             Sequences (5'--3')
  ---------------- -----------------------
  *q-DRAM2-F*      GTTATCTGGTGTGGAGTAAGT
  *q-DRAM2-R*      GTAGCCGTGTTCGTTCAT
  *q-GAPDH-F*      ACCCCGCCGCCTGTGGAGG
  *q-GAPDH-R*      TTCTGACGGCAGGTCAGGT
  *Si-DRAM2-F*     GCAATGCTAAATATTGCGG
  *Si-DRAM2-R*     CCGCAATATTTAGCATTGC
  *Si-Control-F*   CCTTCGATATAATTATTGC
  *Si-Control-R*   GCAATAATTATATCGAAGG
  *cDNA-DRAM2-F*   CAACCTGACGTGCACCAATC
  *cDNA-DRAM2-R*   CCTACAGGTGCCTCTCTCCT

q -- used in qRT-PCR, Si -- siRNA, F -- forward primer, R -- reverse primer.

MTT assay {#sec2.6}
---------

Cell viability was assessed by using 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. 3000 cells in 100 µl of medium per well were seeded in 96-well plates. Cells were cultured for 24 h, 48 h, 72 h, 96 h, and then incubated with 0.5 mg/ml of MTT at 37°C for 4 h. Medium was replaced with 150 µl DMSO per well to dissolve the precipitates. Colorimetric analysis using a 96-well micro-plate reader (Bio Tek) was performed at wavelength of 490 nm. An effect curve was drawn and the IC50 value of gemcitabine to bladder cancer cells was calculated depending on cell proliferation and drug concentration.

Transmission electron microscopy {#sec2.7}
--------------------------------

Cells were treated with BIX-01294 1 µM and then fixed in Karnovsky's fixative (2% paraformaldehyde and 5% glutaraldehyde in 0.1 M cacodylate, pH 7.4) followed by osmium tetroxide. Samples were then dehydrated in ethanol, infiltrated and embedded with TAAB Low Viscosity Resin (TLV) mixture at 60°C for 24 h and sectioned to 80 nm in thickness on 300 mesh copper slot grids. Analysis was performed by transmission electron microscopy (JEOL, JEM-1400) at 60 kV.

Apoptosis analysis {#sec2.8}
------------------

Apoptotic cells were stained using Annexin V-FITC/Propidium Iodide (PI) contained in the Apoptosis Kit (KeyGene Biotech, Nanjing, China). After 48 h of transfection, T24/T24-GEM cells were stained with 5 µl Annexin V-FITC and 5 µl of PI and cultured in the dark at room temperature for 15 min. These cells were analyzed by flow cytometry, and results were processed with CellQuest Pro software (BD Biosciences, San Jose, CA, USA).

Statistical analysis {#sec2.9}
--------------------

Statistical analyses were performed using GraphPad Prism software v. 6.0 (GraphPad Prism software Inc., La Jolla, CA, USA). Data are presented as mean ± SEM (standard error of mean). All experiments were performed in triplicate and repeated at least three times. The unpaired Student's *t*-test was used for comparison of two groups, and one-way ANOVA was performed to analyze differences among more than two experimental groups. Statistical significance was labeled as: \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.

Results {#sec3}
=======

DRAM2 was up-regulated in gemcitabine-resistant cells {#sec3.1}
-----------------------------------------------------

Differentially expressed genes in six cell lines are listed in [Table II](#t0002){ref-type="table"}, *DRAM2* highly expressed in T24-GEM cells and lowly expressed in T24 cells. The *P*-value was computed using the *t*-test, and fold changes of gene expression were calculated by the ratio of the average expression level between drug-resistant and drug-sensitive groups ([Table III](#t0003){ref-type="table"}). The fold change value of *DRAM2* between T24 cells and T24-GEM cells was 2^--0.9224^, and the *p*-value was less than 0.05. Information of related genes in the heatmap, including full name, position and ID, is shown in [Table IV](#t0004){ref-type="table"}. Five genes were highly expressed in the T24 cells and lowly expressed in T24-GEM cells, and four genes were lowly expressed in T24 cells and highly expressed in T24-GEM cells, including *DRAM2* ([Figure 1 A](#f0001){ref-type="fig"}, *p* \< 0.05). Due to three other genes being expressed both in humans and yeast, the *DRAM2* gene was selected as the target gene for further study. The IC50 value of T24-GEM cells (9.953 µg/ml) was significantly higher than that of T24 cells (2.366 µg/ml), and the cell viability of T24-GEM cells was significantly higher than that of T24 cells after treatment with gemcitabine ([Figure 1 B](#f0001){ref-type="fig"}, *p* \< 0.01). Also, protein expression of DRAM2 in T24-GEM cells was higher than that of T24 cells, which was consistent with the results of microarray analyses ([Figure 1 C](#f0001){ref-type="fig"}).

###### 

Relative expression values of differential genes

  Gene        T24_gemcitabine.resistant_1   T24_gemcitabine.resistant_2   T24_gemcitabine.resistant_3   T24_1       T24_2       T24_3
  ----------- ----------------------------- ----------------------------- ----------------------------- ----------- ----------- -----------
  *ATG9B*     --0.58597                     --0.28833                     --0.58597                     0.169592    0.431298    0.64276
  *ATG12*     --0.39833                     --0.39833                     --0.39833                     0.291868    0.054718    0.984777
  *ATG4D*     --0.21256                     0.169592                      --0.11866                     0.984777    0.984777    0.054718
  *ATG13*     --0.11866                     --0.25988                     --0.28833                     0.64276     0.506704    0.291868
  *ATG16L1*   --0.28833                     --0.21256                     --0.06436                     0.506704    0.169592    0.343298
  *ATG7*      0.431298                      0.64276                       0.506704                      --0.28833   --0.21256   --0.39833
  *DRAM1*     0.984777                      0.343298                      0.431298                      --0.11866   --0.39833   --0.25988
  *DRAM2*     0.64276                       0.506704                      0.64276                       --0.39833   --0.28833   --0.28833
  *ATG10*     0.506704                      0.984777                      0.984777                      --0.58597   --0.58597   --0.58597

Negative values (--) denote low expression and positive ones denote high expression.

###### 

Results of fold-change and *p-*value of differential genes

  Gene symbol   logFC        *P-*value     adj. *P-*value
  ------------- ------------ ------------- ----------------
  *ATG9B*       --0.901304   0.000252951   0.001011803
  *ATG12*       --0.842114   0.001995655   0.004561498
  *ATG4D*       --0.728634   0.009445382   0.01679179
  *ATG13*       --0.702731   0.001070063   0.002853502
  *ATG16L1*     --0.528279   0.00794332    0.01588664
  *ATG7*        0.82666      0.000201318   0.001011803
  *DRAM1*       0.84541      0.000836573   0.002677033
  *DRAM2*       0.9224       6.02E-05      0.000481658
  *ATG10*       1.41139      2.45E-06      3.91E-05

Negative values (--) denote low expression and positive denote high expression. LogFC represents the gene expression fold change of T24 cells compared with T24 gemcitabine resistant cells. P-value and adj. p-value refer to statistical values, p \< 0.05 indicates statistical significance.

###### 

Detailed information of the differential genes

  Genes       Full name                                    Position                    ID
  ----------- -------------------------------------------- --------------------------- --------------
  *ATG9B*     ATG9 autophagy related 9 homolog B           chr7:150720259-150720200    NM_173681
  *ATG12*     ATG12 autophagy related 12 homolog           chr5:115167432-115167373    NM_004707
  *ATG4D*     ATG4 autophagy related 4 homolog D           chr19:10663725-10663784     NM_032885
  *ATG13*     ATG13 autophagy related 13 homolog           chr11:46690061-46690120     NM_001205119
  *ATG16L1*   ATG16 autophagy related 16-like 1            chr2:234202948-234203007    NM_030803
  *ATG7*      ATG7 autophagy related 7 homolog             chr3:11468321-11468380      NM_006395
  *DRAM1*     DNA-damage regulated autophagy modulator 1   chr12:102317112-102317171   NM_018370.2
  *DRAM2*     DNA-damage regulated autophagy modulator 2   chr1:111662564-111662505    NM_178454.5
  *ATG10*     ATG10 autophagy related 10 homolog           chr5:81550614-81550673      NM_001131028

![*DRAM2* was up-regulated in gemcitabine-resistant cells. **A** -- The heat map showed that *DRAM2* was up-regulated in gemcitabine-resistant cells. **B** -- The IC50 of T24-GEM cells (9.953 μg/ml) was significantly higher than that of T24 cells (2.366 μg/ml), and the cell viability of T24-GEM cells was higher compared with T24 cells. **C** -- The expression level of *DRAM2* in T24-GEM cells was remarkably higher than that in T24 cells as examined by western blot. \*\**P* \< 0.01 compared with T24 cells](AMS-16-5-40131-g001){#f0001}

Silencing of DRAM2 increased the sensitivity of T24-GEM cells to gemcitabine and inhibited autophagy {#sec3.2}
----------------------------------------------------------------------------------------------------

To determine whether *DRAM2* plays a role in the regulation of cellular autophagy and apoptosis in response to gemcitabine, siRNA against *DRAM2* and control siRNA were transfected into T24-GEM cells. We observed a decrease in the expression of mRNA and protein after knockdown of *DRAM2* ([Figure 2 A, B](#f0002){ref-type="fig"}, *p* \< 0.05). In the *si-DRAM2* group, T24-GEM cells became more sensitive to gemcitabine-induced damage with the IC50 level decreasing from 9.953 µg/ml to 2.266 µg/ml ([Figure 2 C](#f0002){ref-type="fig"}, *p* \< 0.01). We also investigated the viability and apoptosis of these cells using MTT and flow cytometry. The results showed that under the treatment of 0.5 µg/ml gemcitabine, *DRAM2*-knockdown cells were less active compared with si-Con cells ([Figure 2 D](#f0002){ref-type="fig"}, *p* \< 0.01), and the number of apoptotic cells increased ([Figure 2 E](#f0002){ref-type="fig"}, *p* \< 0.01). Also, the number of autophagosome decreased ([Figure 2 F](#f0002){ref-type="fig"}). LC3 I level increased while LC3 II level decreased ([Figure 2 G](#f0002){ref-type="fig"}). These results suggested that silencing of *DRAM2* decreased T24-GEM cells' sensitivity to gemcitabine and inhibited autophagy.

###### 

Knockdown of *DRAM2* increased the sensitivity of T24-GEM cells to chemotherapy and inhibited autophagy. **A** -- The expression of *DRAM2* in T24-GEM cells significantly decreased after transfection with si-*DRAM2* as measured by qRTPCR. **B** -- The expression of *DRAM2* in T24-GEM cells significantly decreased after transfection with si-DRAM2 as measured by western blot. **C** -- T24-GEM cells became more sensitive to gemcitabineinduced damage with the IC50 level decreasing from 9.953 μg/ml to 2.266 μg/ml after transfection with si-*DRAM2*. **D** -- The cell growth of T24-GEM cells transfected with si-*DRAM2* was suppressed significantly confirmed by MTT assay. **E** -- The apoptosis rate of T24-GEM cells in si-*DRAM2* groups significantly increased in comparison with the si-Con group as detected by flow cytometry **F** -- The number of autophagosome in T24-GEM cells in si-*DRAM2* groups obviously decreased as shown by transmission electron microscopy. **G** -- Autophagy markers LC3 I/II of T24-GEM cells in si-*DRAM2* groups significantly increased as detected by western blot. NC -- negative control group, T24-GEM cells were transfected with Lipofectamine 2000 reagent. Si-Con -- siRNA control group, T24-GEM cells were transfected with siRNA control sequence. si-*DRAM2* -- si-*DRAM2* group, T24 cells were transfected with si-*DRAM2* sequence. \*\*P \< 0.01 compared with si-Con group

![](AMS-16-5-40131-g002)

![](AMS-16-5-40131-g003)

Over-expression of DRAM2 decreased the sensitivity of T24 cells to gemcitabine and promoted autophagy {#sec3.3}
-----------------------------------------------------------------------------------------------------

Plasmids of pcDNA 3.1 and pcDNA 3.1-*DRAM2* were transfected into T24 cells. Over-expression of *DRAM2* increased the expression of mRNA and protein ([Figures 3 A, B](#f0003){ref-type="fig"}, *p* \< 0.01). We also investigated the cell viability using MTT assays. The results showed that after over-expression of *DRAM2*, the IC50 value increased to 3.595 µg/ml, which was much higher than that in the pcDNA3.1 group (1.672 µg/ml, [Figure 3 C](#f0003){ref-type="fig"}, *p* \< 0.01). These observations showed that the sensitivity to gemcitabine in T24 cells significantly decreased after over-expression of *DRAM2*. With the treatment of 0.5 µg/mL gemcitabine, cells transfected with *DRAM2* were more active than cells in the pcDNA3.1 group ([Figure 3 D](#f0003){ref-type="fig"}, *p* \< 0.01), and the number of apoptotic cells decreased while autophagosomes increased ([Figures 3 E, F](#f0003){ref-type="fig"}, *p* \< 0.01). Additionally, LC3 I expression level decreased while LC3 II expression level increased ([Figure 3 G](#f0003){ref-type="fig"}). These results suggested that over-expression of *DRAM2* decreased the sensitivity of T24 cells to gemcitabine and promoted autophagy.

###### 

Over-expression of *DRAM2* decreased the sensitivity of T24 cells to chemotherapy and promoted autophagy. **A** -- The expression of *DRAM2* in T24 cells dramatically increased after transfection with pcDNA3.1-*DRAM2* as observed by qRT-PCR. **B** -- The expression of *DRAM2* in pcDNA3.1 group of T24 cells was significantly higher than that in the pcDNA3.1 group as detected by western blot. **C** -- After over-expression of *DRAM2*, the IC50 value increased to 3.595 μg/ml, which was much higher than that in the pcDNA3.1 group. **D** -- MTT assay showed that cell proliferation of T24 cells was significantly enhanced in the *DRAM2* overexpression group compared with the pcDNA3.1 group. **E** -- Compared with the pcDNA3.1 group, the apoptosis rate of T24 cells drastically increased after transfection with pcDNA3.1-*DRAM2* as detected by flow cytometer **F** -- The number of autophagosome in T24 cells in the pcDNA3.1-*DRAM2* group obviously increased as shown by transmission electron microscopy. **G** -- Autophagy markers LC3 I/II of T24 cells in pcDNA3.1-*DRAM2* groups significantly decreased as detected by western blot. NC -- negative control group, T24 cells were transfected with the Lipofectamine 2000 reagent. pcDNA3.1 -- pcDNA3.1 control group, T24 cells were transfected with empty pcDNA3.1 vector. pcDNA3.1-*DRAM2* -- pcDNA3.1-*DRAM2* group, T24 cells were transfected with pcDNA3.1-*DRAM2*. \*\*P \< 0.01 compared with NC group
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Discussion {#sec4}
==========

Drug resistance is the major cause of the failure of clinical effectiveness of chemotherapy for bladder cancers. For example, cisplatin is one of the most effective bladder cancer agents, while inherent and acquired resistance limits its application \[[@cit0014]\]. The pyrimidine analog gemcitabine, alone or in combination with other drugs, is the current standard of care for advanced TCC. However, the response to gemcitabine in patients is very poor, with no drastic reduction in metastasis or increase in the survival rate of patients \[[@cit0015]\]. Multiple molecular mechanisms of gemcitabine resistance encompassing different pathways have been suggested. Recently, Geller *et al.* hypothesized that intratumor bacteria might contribute to drug resistance of pancreatic ductal adenocarcinoma (PDAC) \[[@cit0016]\]. Amantini *et al.* demonstrated a mechanism of chemoresistance by which cancer cells increase intracellular cytidine pools that can in turn render gemcitabine ineffective by molecular competition \[[@cit0017]\]. Many studies have documented genetic aberrations in the development of BTCC, including point mutations of the *TP53* \[[@cit0018]\], *FHIT* \[[@cit0019]\], *KAI1* \[[@cit0020]\], *BCL-2* and *BCL-X* genes \[[@cit0021]\]. Here, by screening the differentially expressed genes between T24 cells and T24-gemcitabine-resistant cells, *DRAM2*, DNA-damage regulated autophagy modulator 2, was found to be up-regulated in gemcitabine-resistant cells in our study.

*DRAM2*, a critical regulator of autophagy, encodes a transmembrane lysosomal protein thought to play a role in the initiation of autophagy \[[@cit0008]\]. It has been reported that *DRAM2* expression is frequently dysregulated in cancers and that over-expression of *DRAM2* induces autophagy \[[@cit0022]\]. *DRAM2* was more highly expressed in gastric cancer (GC) tissues than in matched normal tissues \[[@cit0023]\]. Importantly, the knockdown phenotypes for *DRAM2* inhibited autophagy and arrested myeloid cell differentiation in an acute promyelocytic leukemia (APL) mouse model \[[@cit0024]\]. The *DRAM2*-dependent autophagic cascade affects Hodgkin lymphoma (HL) cell proliferation and tumor growth \[[@cit0024]\]. Yoon *et al.* demonstrated that silencing of endogenous *DRAM2* interferes with starvation-induced autophagy \[[@cit0022]\]. Similarly, our results showed that *DRAM2* was up-regulated in T24-gemcitabine-resistant cells, which enhanced cell viability and inhibited cell apoptosis in T24-gemcitabine-resistant cells.

Dysregulated autophagy is highly prevalent in many types of cancer including drug-resistant bladder cancer and has been implicated in cytoprotection and tumor death \[[@cit0025]--[@cit0027]\]. Exploring the mechanism of gemcitabine resistance in bladder cancer from the perspective of autophagy may provide a brand new insight into solving the problem of drug resistance in bladder cancer. Previous studies have focused on suppressing autophagy-related genes or using autophagy inhibitors to strongly potentiate gemcitabine-induced apoptosis and inhibiting gemcitabine-induced autophagy \[[@cit0028]\]. Conflicts and controversies are often accompanied by studies of cancer cell autophagy. Some studies have indicated that in cancer autophagy exerts cytoprotective effects \[[@cit0029]--[@cit0031]\], whereas others suggest that autophagy positively contributes to cell death by enhancing cytotoxicity of anticancer drugs \[[@cit0032]--[@cit0034]\].

Our study firstly researched the dysregulated expression of the autophagy-related gene *DRAM2* in T24 cells and T24-gemcitabine-resistant cells and explored resistance of gemcitabine altered through the regulation of *DRAM2*. Similar to studies of autophagy, studies on *DRAM2* remain disputatious. In contrast to our results, Park *et al.* pointed out that expression of *DRAM* or *DRAM2* individually did not induce cell death, co-expression of *DRAM2* with *DRAM* significantly induced cell death, while the silencing of endogenous *DRAM2* attenuated cell death \[[@cit0035]\]. These conflicts may be caused by the stage and type of the cancer cells and the ignorance about drug-induced autophagy. Our study investigated the effects of *DRAM2* on gemcitabine-resistant bladder cell biology. However, some limitations still exist. For instance, we only examined *DRAM2* functions, while other genes and factors are also worth studying, such as micronutrients \[[@cit0036]\]. Furthermore, the pathway of *DRAM2* in gemcitabine-resistant bladder cells needs to be clarified by future work.

In conclusion, overall, the current study demonstrated that *DRAM2* was up-regulated in gemcitabine-resistant bladder cancer T24 cells. *DRAM2* silence in T24-GEM cells promoted apoptosis whereas it inhibited autophagy and decreased the cell viability and resistance to gemcitabine, while in T24 cells, overexpression of *DRAM2* promoted autophagy and cell viability but inhibited cell apoptosis and sensitivity to gemcitabine. These results allowed us to speculate that up-regulation of *DRAM2* may confer on gemcitabine-resistant bladder cancer cells an advantage of insensitivity to gemcitabine. Therefore, the treatment of bladder cancer with gemcitabine in combination with drugs targeting the autophagic gene *DRAM2* could represent an interesting new approach in bladder cancer therapy.
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